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Editorial
Neoadjuvant chemotherapy for unresectable liver metastases of
colorectal cancer - too good to be true?
At present, surgery is the only curative treatment for
liver metastases from colorectal cancer. Five-year sur-
vival has been 20%-45% after hepatic resection in the
largest series published to date [1]. Extent and location
of the metastases determine resectability and presence
of extrahepatic disease is a strong prognostic factor for
poor outcome [1], although the resection of synchronous
lung metastases is possible in selected patients [2, 3].
Liver metastases from other primary tumor sites are
generally a reflection of disease dissemination and
surgery is not considered a curative treatment option
anymore in these cases. The situation is different with
colorectal cancer, where the portal venous drainage
system favors metastases to the liver without systemic
dissemination. In addition, metastatic inefficiency leads
to the destruction of a majority of metastatic deposits
within blood vessels or lymphatic channels and has been
taken as an explanation for the confined metastastic
potential of colorectal cancer [4].
Liver involvement is an important problem in colo-
rectal cancer, which is present in 40%-70% of patients
with metastatic disease. However, the liver is the sole
site of metastases in only about half of the cases [5-7].
Stangl et al. determined the natural history of colorectal
liver metastases in a recent prospective series on 1099
patients. Thirty-one percent of the patients underwent
liver resection and complete tumor clearance was
achieved in 78% of those cases. The five-year survival
was 32% after hepatic resection. In contrast, if surgery
was not possible the median survival of patients receiv-
ing chemotherapy or no treatment was 12 and 7.5
months, respectively [8]. It can be concluded from this
and other large series, that unresectable liver metastases
from colorectal cancer are nearly always fatal within
five years [5]. After liver resection, about 40% of the
recurrences seem again confined to the liver [1] and a
three-year survival of 33% has been reported in this
situation [9]. However, more often relapses occur outside
the liver. This underlines the need for better diagnostic
tools to screen patients for extrahepatic disease before
surgery. Promising options are whole-body positron emis-
sion tomography with (fluorine- 18)-2-fluoro-2-deoxy-D-
glucose [10] or the detection of genetic material of micro-
metastases by molecular amplification methods [11].
Despite the fact, that adjuvant chemotherapy has been
proven very successful in primary colorectal cancer [12],
there is only recent evidence of a benefit after liver surgery
[13, 14].
Clinical prognostic factors are of limited practical use
to select suitable patients for hepatic resection, which
have a low risk for extrahepatic disease. Fong et al.
identified positive resection margin, size greater than 10
cm, disease-free interval less than 12 months, multiple
tumors, and extrahepatic disease as independent predic-
tors of poorer outcome by multivariate analysis [1].
However, a good outcome was possible even in the
presence of poor prognostic factors and it is doubtful
whether individual patients should be precluded from
surgery on the bases of prognostic factors alone. Taking
all these uncertainties into consideration, it is fortunate,
that the growing expertise in hepatic surgery has helped
to bring down the mortality rate of this procedure close
to zero [1, 15, 16]. In experienced centers, the choice of
hepatic resection is rarely a fatal decision these days.
What can we offer, if liver metastases from colorectal
cancer are not resectable in the first place? The standard
approach in this situation is systemic chemotherapy,
which is based on fluorouracil since more than four
'decades. Treatment with fluorouracil alone has resulted
in response rates of about 10% as demonstrated by
the results of two meta-analyses [17, 18]. Among all
chemotherapy combinations in clinical use, only biomo-
dulation of fluorouracil with leucovorin or methotrexate
has translated into significantly higher response rates
(19%—23%) and prolonged survival compared to fluorour-
acil alone [17-20]. On the background of such modest
results, the pessimistic attitude of the medical commun-
ity towards the treatment of advanced colorectal cancer
is understandable [21].
Only recently, new and exciting treatment options
have become available for colorectal cancer. Irinotecan
and oxaliplatin, two drugs, which are unrelated to
fluorouracil, have shown clear activity even after failure
of fluorouracil [22, 23]. Oxaliplatin, a 1,2-diaminocyclo-
hexane platinum compound, has demonstrated repro-
ducible synergistic activity with fluorouracil. In non-
pretreated patients, oxaliplatin with fluorouracil and
leucovorin has resulted in response rates from 34% to
67% [23]. This treatment combination has also been
used to test the exciting concept of chronomodulation,
which is based on the observation that the differential
proliferative activity of normal and tumor cells as well as
the metabolic (de)activation of drugs is subjected to
circadian rhythms [24]. Higher doses can be given, if
drug delivery is adjusted to the circadian rhythm of
tissue tolerability. In a randomized study in metastatic
colorectal cancer, patients treated with chronomodulated
chemotherapy with oxaliplatin, fluorouracil, and leuco-
vorin achieved a significant benefit in terms of response
rate (51% versus 29%), toxicity, and median time to treat-
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ment failure compared to constant-rate infusion of the
same drugs. The fact, that a higher dose intensity for both
fluorouracil and oxaliplatin could be achieved in the
chronotherapy arm is possibly responsible for the better
antitumor effect compared to constant-rate infusion
[25].
Having this potent chemotherapy regimen at hand, a
group of expert chronotherapists and liver surgeons
developed a novel neoadjuvant treatment concept for
unresectable liver metastases from colorectal cancer.
The paper of Giacchetti et al. in this issue reports their
experience with a median follow-up of 5.5 years [26].
Treatment with mostly chronomodulated oxaliplatin,
fluorouracil, and leucovorin resulted in a response rate
of 59% and most of these patients (78%) could be
resected with tumor-free resection margins. The estimated
five-year survival after neoadjuvant chemotherapy and
surgery was 58%. The prognostic importance of resect-
ability is underlined by the results of the multivariate
analysis and the fact, that the median survival was 15.5
months in non-operated patients, while it has not been
reached yet in the resected group. A median of 5.5
months of chemotherapy was necessary to achieve opti-
mal preoperative tumor reduction. In four cases, patho-
logically complete responses occurred. Thirty-one per-
cent of all patients screened for surgery could be radically
resected. 20% of the resected patients did not relapse,
whereas the exact timeframe of this observation is not
given. Relapses occurred early, after a median time of
12 months with a range of 9-16 months. In a third of the
relapsed patients repeat hepatic resection was possible
for recurrences confined to the liver.
The interpretation of a retrospective series such as
the one by Giacchetti et al. [26] is a teaching exercise for
all sorts of traps and biases, the thourough discussion of
which would be all too nit-picking in view of the novelty
of the concept of neoadjuvant chemotherapy in colo-
rectal cancer. The bottom line, however, is whether we
can trust the initial surgical assessment of resectability.
Obviously, if resectable liver metastases would have been
erroneously declared inoperable at first assessment, this
study could easily turn meaningless. Fortunately, the
surgeons involved in the study belong to the leaders in
their field and the chance of misjudgement is remote.
Still, the initial resectability must have been on the edge
in some cases, since 16 patients turned resectable after
only minor (25%-49%) responses to chemotherapy and
6 even after less than 25% tumor reduction. There is also
the question of selection bias, since only 35% of the
patients had ^ 25% liver involvement. The extent of
hepatic replacement by tumor is the most important
determinant for survival in colorectal cancer metastatic
to the liver [8, 27] and relatively low-risk patients might
have been preferentially included in this study. However,
even these caveats in mind, the five-year survival reported
in this paper is very impressive compared to other series
on patients with inoperable liver metastases [5, 8. 27].
On the background of the generally sombre outlook for
patients with inoperable liver metastases from colorectal
cancer, already the message, that better prognosis patients
can be selected, is a promising message.
Where can we go from here? Before neoadjuvant
chemotherapy can be adopted as standard treatment for
unresectable colorectal cancer liver metastases, it would
be helpful to have results from prospective series and
data from independent centers. The authors of such
series should not hesitate to give a detailed listing of the
number, size, location and reason for unresectability for
each liver metastasis in addition to response to chemo-
therapy and long-term outcome after resection. We need
information, whether chemotherapy can 'cure' individu-
al metastases or increases resectability only by allowing
wider resection margins because of tumor shrinkage. If
complete and durable pathological responses can be
induced in individual metastases, it might be possible to
limit the resection to metastatic sites, which persist after
chemotherapy. This should further increase the rate of
technically resectable patients. A recent case report has
demonstrated complete disappearance of liver metastases
after hepatic arterial infusion chemotherapy alone with-
out evidence for relapse after more than eight years [28].
The usual call for a large randomized phase III study
must probably go unheard for liver resection after neo-
adjuvant chemotherapy, since it will never be possible
to perform a trustworthy trial in view of the inherent
methodological problems. It would be difficult and
probably unethical to convince a patient in the control
arm of such a study to leave potentially resectable
metastases after chemotherapy unresected. In addition,
surgical expertise is nearly impossible to control for as
has shown a recent study assessing the value of extended
lymph-node dissection for gastric cancer [29].
How can we optimize neoadjuvant chemotherapy? The
optimal dose, schedule, and combination of oxaliplatin,
irinotecan, and fluorouracil plus leucovorin, the pres-
ently most effective drugs in colorectal cancer, will have
to be assessed. Neoadjuvant treatment should also bring
the concept of hepatic arterial infusion (HAI) to a
reappraisal. One of the important rationales for HAI is
the fact, that liver metastases derive their blood supply
mainly from the hepatic artery, while normal liver
parenchyma is supplied predominantly by the portal vein
[30]. HAI with fluoropyrimidines alone has led to much
higher (41% versus 14%) response rates in the treatment
of nonresectable liver metastases compared to intrave-
nous treatment [31]. In addition, the systemic toxicity of
chemotherapy can be diminished by HAI and the dose
intensity can be improved due to the metabolic function
of the liver. Despite these obvious merits, the role of
HAI in the treatment of colorectal cancer has remained
controversial since a clear survival benefit compared to
systemic treatment could not be demonstrated [31].
Hovvever, for the purpose of selecting a useful neoadju-
vant chemotherapy regimen, response rate rather than
survival should be the primary endpoint. Chemoembo-
lization exploits the predominantly arterial blood supply
of liver metastases even further, since it combines
chemotherapy with the ischemic effect of vascular occlu-
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sion, but this approach can be associated with consid-
erable liver toxicity [32]. For drugs with a dose-response
relationship and a high potential of systemic toxicity,
isolated perfusion of the liver is an option, which allows
to give as much drug as can be tolerated by the normal
liver parenchyma without systemic exposure [33]. In
addition to conventional drugs, biomolecules with cyto-
toxic potential or with chemosensitizing properties such
as vectors containing wild-type p53 will also be ready
for regional administration through the hepatic artery in
the near future [34].
With this multitude of neoadjuvant treatment options
for liver metastases, resources will have to be allocated
wisely. Rather than spending hundreds of patients on a
non-conclusive randomized study with an arbitrary ex-
perimental arm, well performed phase II trials should be
encouraged with detailed description of disease parame-
ters and long-term outcome. Giacchetti et al. can take
credit for providing the participation in such studies
with the incentive of five-year survival [26].
M. M. Borner
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Molecular biology of B-cell and T-cell development.
J. G. Monroe, E. V. Rothenberg (eds). Humana Press
Inc.,Totowa, NJ, USA, 1998. 601 pp, $125.00.
In recent years, our knowledge concerning the ontogeny
of B and T cells has greatly expanded. New information
about lymphocyte development has had a significant
impact on our understanding of human cancer and on
the design of novel therapeutic approaches. Cell surface
markers allow us to identify many of the steps in lym-
phocyte development, and molecular biology provides
the techniques for studying the weight of single-gene
products along this pathway. All of the new biological
data emphasize that lymphomas, which derive from the
neoplastic transformation of lymphocytes at different
stages of maturation, are necessarily a heterogeneous
group of diseases.
The book edited by Monroe and Rothenberg gives us
a detailed overview of the ontogeny of B and T cells. Its
first 24 chapters cover the development of lymphocytes,
explaining the role of different transcription factors, and
describing interactions among hematopoietic cells and
microenvironmental factors (non-hematopoietic cells,
cytokines, extracellular matrix) and systemic factors,
such as the endocrine system. The final three chapters
provide examples of the clinical application of the new
knowledge: stem cell transplantation for hematopoietic
neoplasms, possible uses of placental blood and gene
therapy for immunologic disorders.
References are plentiful and updated to 1997. My
major criticism of the book is that it covers almost
exclusively the early phases of B- and T-cell development
while excluding any discussion of the features of periph-
eral lymphocytes.
'Molecular biology of B-cell and T-cell development'
can unequivocally be recommended to people involved
in the study of lymphocytes and lymphoma research.
The topics covered in this volume provide a comprehen-
sive view of the most relevant advances in the field.
However, if a clinician is seeking an introduction to the
molecular mechanisms underlying lymphomas, this book
should not be his or her first choice; for that purpose it is
too complex and basic research-oriented.
F. Bertoni
BeUinzona
